Apexicon E label

Apexicon E

Apexicon E Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

Each gram of ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) contains 0.5 mg diflorasone diacetate in a cream base for topical dermatological use.

Chemically, diflorasone diacetate is: 6α,9-difluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate.

The structural formula is represented below:

Structural Formula

Each gram of ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) contains: 0.5 mg diflorasone diacetate in a hydrophilic vanishing cream base of propylene glycol, stearyl alcohol, cetyl alcohol, sorbitan monostearate, polysorbate 60, mineral oil and purified water.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Apexicon E Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Apexicon E Manufacturers

  • Pharmaderm, A Division Of Nycomed Us Inc.
    Apexicon E | Pharmaderm, A Division Of Nycomed Us Inc.
    No Recall

    Apexicon E | Pharmaderm, A Division Of Nycomed Us Inc.

    Apexicon E | Pharmaderm, A Division Of Nycomed Us Inc.

    ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) should be applied to the affected areas as a thin film from one to three times daily depending on the severity or resistant nature of the condition.

    Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.

  • Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
    Apexicon E | Pharmaderm A Division Of Fougera Pharmaceuticals Inc.
    No Recall

    Apexicon E | Pharmaderm A Division Of Fougera Pharmaceuticals Inc.

    Apexicon E | Pharmaderm A Division Of Fougera Pharmaceuticals Inc.

    ApexiCon® E Cream (diflorasone diacetate cream USP 0.05% [emollient]) should be applied to the affected areas as a thin film from one to three times daily depending on the severity or resistant nature of the condition.

    Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.

Login To Your Free Account